20-Week Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia

NCT01906489 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

210

Enrollment

INDUSTRY

Sponsor class

Conditions

Anemia
Chronic Kidney Disease

Interventions

DRUG: AKB-6548
DRUG: Placebo

Sponsor

Akebia Therapeutics